<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="discussion" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1463399</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Opinion</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular basis and pathways of the Yin-Yang theory in T cell immunity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Xiang</surname>
<given-names>Jim</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2787283"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leary</surname>
<given-names>Scot C.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2799633"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Zhaojia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Michelle</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Cancer Research Cluster, Saskatchewan Cancer Agency</institution>, <addr-line>Saskatoon, SK</addr-line>, <country>Canada</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Division of Oncology, College of Medicine, University of Saskatchewan</institution>, <addr-line>Saskatoon, SK</addr-line>, <country>Canada</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Biochemistry, Microbiology and Immunology, College of Medicine, University of Saskatchewan</institution>, <addr-line>Saskatoon, SK</addr-line>, <country>Canada</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Tara Marlene Strutt, University of Central Florida, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Maria N. Navarro, Spanish National Research Council (CSIC), Spain</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Jim Xiang, <email xlink:href="mailto:jim.xiang@usask.ca">jim.xiang@usask.ca</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>11</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1463399</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>07</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>11</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Xiang, Leary, Wu and Yu</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Xiang, Leary, Wu and Yu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<kwd-group>
<kwd>Yin-Yang theory</kwd>
<kwd>T cell immunity</kwd>
<kwd>molecular mechanisms</kwd>
<kwd>signaling pathways</kwd>
<kwd>mTORC1</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="38"/>
<page-count count="6"/>
<word-count count="2622"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>T Cell Biology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>The Yin-Yang theory represents a fundamental principle in traditional Chinese medicine (TCM), guiding its diagnosis and treatment of diseases (<xref ref-type="bibr" rid="B1">1</xref>). In the latter context, the Yin element refers to reserve, healing, resting or quiescence, passive or inhibitory factors and negative regulation while the Yang element speaks to consumption, working or activeness, growth or promoting factors and positive regulation. The theory posits that a balance between these two opposing forces becomes the premise of a healthy body (<xref ref-type="bibr" rid="B1">1</xref>). The &#x201c;Qi&#x201d;, a special energy flowing in the body, is a driver of the defense system in TCM (<xref ref-type="bibr" rid="B1">1</xref>), and is analogous to the protective immune system in Western medicine (WM). However, there is a huge gap between the conceptional connection of TCM and WM.</p>
<p>The Yin-Yang theory has been applied historically to interpret immune system biology mostly from the perspective of the counteractive features of these two immune elements or responses. For example, the suppressive CTLA-4 and immunogenic CD28 have been described as the Yin and Yang of T cell co-stimulation (<xref ref-type="bibr" rid="B2">2</xref>). Moreover, CD4<sup>+</sup> Treg and CD4<sup>+</sup> Th1 cells have been considered to belong to Yin and Yang CD4<sup>+</sup> T cell subsets, where the former and latter cells contribute to tolerant and active immune responses, respectively (<xref ref-type="bibr" rid="B3">3</xref>). More recently, the regulators AMPK&#x3b1;1 and mTORC1 have been proposed to represent Yin and Yang energy sensors, with mTORC1 signaling the availability of nutrients and promoting immune stimuli that support cell proliferation through glycolysis and AMPK&#x3b1;1 signaling a lack of nutrients and inhibiting cell growth through FAO metabolism (<xref ref-type="bibr" rid="B4">4</xref>). However, the molecular basis and pathways underpinning the Yin-Yang theory in T cell immunity remain incompletely understood.</p>
<p>mTORC1 is an evolutionarily conserved serine/threonine kinase whose ability to sense three major immune signals (i.e. antigen, co-stimulation, and cytokines) and a variety of environmental cues (e.g. growth factors and nutrient status) allows it to act as a master regulator. Its activity is modulated in a phosphorylation-dependent manner by PI3K-Akt signaling. PI3K phosphorylates PIP2 at the cell surface to generate PIP3, which recruit and phosphorylate Akt at T<sub>308</sub> through PDK1 (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) (<xref ref-type="bibr" rid="B5">5</xref>). mTORC2 can also be activated by PI3K through PIP3 and phosphorylated at S<sub>473</sub> (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>), that confers for a full activation and substrate specificity of Akt (<xref ref-type="bibr" rid="B6">6</xref>). The phosphorylation of Akt at T<sub>308</sub> triggers mTORC1 signaling, which in turn up-regulates the downstream substrates ribosomal S6K1 and S6K2 and eIF4E to modulate protein synthesis, cell proliferation, metabolism and differentiation (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) (<xref ref-type="bibr" rid="B7">7</xref>), whereas the phosphorylation of Akt at S<sub>473</sub> represses FOXO1 activity through phosphorylation of FOXO1 at T<sub>24</sub> (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) (<xref ref-type="bibr" rid="B8">8</xref>). Autophagy is a self-recycling process in which cellular constituents are degraded by lysosomes to provide essential anabolic building blocks in support of metabolism and homeostasis under stress conditions (<xref ref-type="bibr" rid="B9">9</xref>). Flux through autophagy as well as most branches of intermediary metabolism, including mitochondrial FAO, is regulated by the activity of the evolutionarily conserved energy sensor AMPK&#x3b1;1, which is in turn controlled by LKB1, CaMKK2, PKA and TAK-1 (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) (<xref ref-type="bibr" rid="B9">9</xref>). As such, AMPK&#x3b1;1 is central to CD8<sup>+</sup> T<sub>M</sub> cell formation (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) (<xref ref-type="bibr" rid="B9">9</xref>). FOXO1 is another well known, key regulator that controls various aspects of cell development (<xref ref-type="bibr" rid="B10">10</xref>) and also contributes to CD8<sup>+</sup> T<sub>M</sub> cell differentiation (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) (<xref ref-type="bibr" rid="B8">8</xref>). Both AMPK&#x3b1;1 and FOXO1 were also described as tumor suppressors because of their inhibitory effect on tumor growth (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>). Therefore, AMPK&#x3b1;1/FOXO1 and AKT/mTORC1 can be characterized as Yin and Yang master regulators in T cell immunity as well as cell biology (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Molecular basis and pathways of the Yin-Yang theory in T cell differentiation and metabolism. <bold>(A)</bold> Schematic diagram illustrating the major, upstream molecular pathways that regulate the activity of the master regulators Yang AKT and mTORC1 and Yin AMPK and FOXO1, which collectively control CD8<sup>+</sup> T cell immunity. Three immune signals, growth factors or nutrients trigger the Yang molecular PI3K-AKT-mTORC1 pathway to control gene expression, protein systhesis and CD8<sup>+</sup> T<sub>E</sub> cell differentiation. AMPK modulates the necessary changes in autophagic flux and FAO metabolism to support CD8<sup>+</sup> T<sub>M</sub> cell differentiation. Yin FOXO1 works in concert with Yin AMPK to regulate development of the CD8<sup>+</sup> T<sub>M</sub> cell phenotype and desired functional effect. Yin AMPK&#x3b1;1/FOXO1 and Yang AKT/mTORC1 exhibit a negative interaction. The Yin AMPK activator metformin activates AMPK (solid line), but inhibits the Yang mTORC1 (dotted line) while the Yang mTORC1 inhibitor rapamycin inhibits mTORC1 (solid line), but activates the Yin FOXO1 (dotted line). <bold>(B)</bold> Metabolic transitions of CD8<sup>+</sup> T cells at different stages of the immune response. Post-infection, quiescent na&#xef;ve CD8<sup>+</sup> T cells enter a developmental program including T cell expansion followed by a contraction phase. During this latter phase, the majority of IL-7R<sup>-</sup>CD62L<sup>-</sup>KLRG<sup>+</sup> T<sub>E</sub> cells die of apoptosis while the remaining T cells differentiate into long-lived IL-7R<sup>+</sup>CD62L<sup>+</sup>KLRG<sup>-</sup> T<sub>M</sub> cells. To meet the bioenergetic demand of T<sub>E</sub> cells during T cell expansion and contration phases, na&#xef;ve T cells switch from mitochondrial respiration with mitochondrial fusion to glycolysis of T<sub>E</sub> cells with mitochondrial fission. During the memory phase, the metabolic program reverts to catabolic FAO as T<sub>E</sub> cells gradually transition to T<sub>M</sub> cells with mitochondrial fusion. <bold>(C)</bold> Basic Yin and Yang immune elements (cells, cytokines, costimulations, growth factors, nutrients, suppressive reagents, activators or inhibitors) and genes in T cell immunity. <bold>(D)</bold> Schematic diagram of how strong or weak strengths of mTORC1 signaling give rise to distinct T cell subtypes. The Yang IL-2 cytokine elicits strong mTORC1 signaling to promote the differentiation of na&#xef;ve T cells into glycolytic Yang IL-7<sup>-</sup>CD62L<sup>-</sup>KLRG<sup>+</sup> T<sub>E</sub> cells by activating the Yang transcriptional T-bet and Yang metabolic HIF-1&#x3b1; pathways. In contrast, the Yin IL-7/IL and 15/IL-2+Rapa cytokines promote the differentiation of na&#xef;ve T cells into Yin T<sub>M</sub> cells that rely on FAO metabolism <italic>via</italic> activation of the Yin transcriptional FOXO1-TCF1-ID3-Eomes and Yin metabolic AMPK-ULK1-ATG7-PCG1&#x3b1; pathways. <bold>(E)</bold> Some basic principles of the Yin-Yang theory in T cell immunity are summarized. All graphs, diagrams and characters in blue and red color represent Yin and Yang, respectively.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1463399-g001.tif"/>
</fig>
</sec>
<sec id="s2">
<label>2</label>
<title>Two basic cellular characteristics determine the Yin and Yang immune cell subsets</title>
<p>In modern T-cell biology, two basic features have been well studied; (i) cellular differentiation into a defined phenotype with respect to form and function, and (ii) metabolic fuel preference to provide the energy necessary to support function and sustain homeostasis. These features or characteristics are thus used as a standard manner of defining Yin and Yang cell subsets in immunity and may even be extended conceptually to various tissues or organs of the body. CD8<sup>+</sup> T-cells play a critical role in immune responses against tumors and infectious diseases. During infection, pathogen-engaged DCs use three distinct signals (antigen, co-stimulation and cytokines) to stimulate catabolic CD8<sup>+</sup> Tn cells to grow and differentiate into one of two CD8<sup>+</sup> T-cell subsets; anabolic IL-7R<sup>&#x2212;</sup>CD62L<sup>&#x2212;</sup>KLRG1<sup>+</sup> T<sub>E</sub> cells which rely on glycolysis, grow rapidly and exhibit effective killing activity, or catabolic and quiescent IL-7R<sup>+</sup>CD62L<sup>+</sup>KLRG1<sup>&#x2212;</sup> T<sub>M</sub> cells which use mild FAO for economical energy supply (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>). Based on the theory, CD8<sup>+</sup> T<sub>M</sub> and T<sub>E</sub> cells can thus be characterized as typical Yin and Yang CD8<sup>+</sup> T-cells, respectively (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1A&#x2013;C</bold>
</xref>).</p>
</sec>
<sec id="s3">
<label>3</label>
<title>Distinct transcriptional and metabolic pathways control Yin and Yang immune cell differentiation and metabolism</title>
<p>The pro-inflammatory IL-2 and pro-survival IL-7 cytokines (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) belong to common &#x3b3;-chain cytokine family. While both trigger the same PI3K-AKT-mTORC1 pathway, IL-2 induces T<sub>E</sub> cell differentiation and IL-7 promotes T<sub>M</sub> cell formation (<xref ref-type="bibr" rid="B11">11</xref>). We recently sought to elucidate the underlying molecular mechanism, and in so doing demonstrated that IL-2 stimulates strong mTORC1 signaling (Yang IL-2/mTORC1<sup>strong</sup>) due to the persistent expression of cell surface IL-2R, which results in IL-2/T<sub>E</sub> cell formation <italic>via</italic> activation of the Yang transcriptional mTORC1-T-bet and metabolic mTORC1-HIF-1&#x3b1; pathways (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>) (<xref ref-type="bibr" rid="B12">12</xref>). In contrast, we observed that IL-7 stimulates weak mTORC1 signaling (Yin IL-7/mTORC1<sup>weak</sup>) due to the transient expression of cell surface IL-7R, which leads to IL-7/T<sub>M</sub> cell differentiation <italic>via</italic> activation of the Yin transcriptional FOXO1-TCF1-ID3-Eomes and metabolic AMPK&#x3b1;1-ULK1-ATG7-PCG1&#x3b1; pathways (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>) (<xref ref-type="bibr" rid="B12">12</xref>). IL-7/mTORC1<sup>weak</sup> signaling also up-regulates the expression of AQP9, CPT1&#x3b1;, Complex I, Bcl6, LAL and TFAM, which are some of the metabolic factors necessary for increased reliance on FAO (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) (<xref ref-type="bibr" rid="B12">12</xref>). This emerging signaling model is further supported by our other recent findings that pro-survival IL-15-stimulated Yin IL-15/T<sub>M</sub> and mTORC1 inhibitor Rapamycin-treated Yin IL-2 (IL-2+Rapa)/T<sub>M</sub> cells also rely on Yin mTORC1<sup>Weak</sup> signaling and FAO while exhibiting a T<sub>M</sub> cell phenotype and long-term survival after their adoptive transfer into C57BL/6 mice (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>) (<xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B15">15</xref>). Like IL-7, IL-15 similarly promotes CD8<sup>+</sup> T<sub>M</sub> cell differentiation by stimulating weak mTORC1 signaling (Yin IL-15/mTORC1<sup>weak</sup>) (<xref ref-type="bibr" rid="B10">10</xref>) and activating the coupled Yin transcriptional FOXO1-ID3-Eomes and metabolic AMPK&#x3b1;1-ULK1-ATG7-PCG1&#x3b1; pathways. Importantly, these IL-15/T<sub>M</sub> cells also showed a robust recall response upon antigen challenge (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>) (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Our data collectively provide the first evidence that distinct strengths of mTORC1 signaling are able to promote T<sub>E</sub> and T<sub>M</sub> cell formation <italic>via</italic> the activation of distinct transcriptional and metabolic pathways (<xref ref-type="bibr" rid="B12">12</xref>&#x2013;<xref ref-type="bibr" rid="B15">15</xref>), and shed light on the molecular mechanisms underpinning the Yin-Yang theory in T-cell immunity (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1D, E</bold>
</xref>a).</p>
</sec>
<sec id="s4">
<label>4</label>
<title>Some other basic principles of the Yin-Yang relationship relevant to T-cell immunity</title>
<p>Some other, basic principles of the Yin-Yang relationship as it pertains to T cell immunity can also be recognized. For example, the Yang master regulator mTORC1 controls the activity of various transcriptional (T-bet, Blimp-1 and ID2) and metabolic (HIF-1&#x3b1; and cMyc) factors. The Yin master regulators FOXO1 (<xref ref-type="bibr" rid="B16">16</xref>) and AMPK&#x3b1;1 similarly exert control over various transcriptional (TCF1, ID3 and Eomes) and metabolic (SIRT1, PGC1&#x3b1;, CPT1&#x3b1;, AQP9, OPA-1, LAL, Complex-I, Bcl6 and TFAM) factors (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B12">12</xref>&#x2013;<xref ref-type="bibr" rid="B15">15</xref>). These data indicate that mTORC1 alone or FOXO1 and AMPK&#x3b1;1 in concert act as master regulators of various downstream targets crucial to the transcriptional and metabolic programs required for T<sub>E</sub> and T<sub>M</sub> cell formation (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>b).</p>
<p>Various Yin and Yang stimuli including cytokines, co-stimulatory molecules, transcriptional and metabolic regulators, repressors, oncogenes and adjuvants among others trigger the maturation of various immune cell subsets and lead to immunotolerant and immunogenic responses, respectively (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1C, E</bold>
</xref>c). For example, the Yin cytokines IL-10 and TGF-&#x3b2; promote the differentiation of CD4<sup>+</sup> Treg, T<sub>M</sub> and CD8<sup>+</sup> T<sub>M</sub> or M2 cells while the Yang cytokines IL-2, IFN-&#x3b3; and IL-12 stimulate immunogenic CD4<sup>+</sup> Th1 and CD8<sup>+</sup> T<sub>E</sub> cell responses (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) (<xref ref-type="bibr" rid="B17">17</xref>&#x2013;<xref ref-type="bibr" rid="B20">20</xref>). The Yin co-stimulatory molecules PD-1, CTLA-4, LAG3, TIM3, BTAL and TIGIT or agonists TLR1, 2, 6 promote suppressive immune responses, while the Yang molecules CD28, CD40, CD80 and CD86 or agonists TLR3, 4, 5, 7, 8 and 9 stimulate active immune responses (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>).</p>
<p>The theory argues for negative interplay between the two elements. For example, the Yang regulators mTORC1 and AKT interact with the Yin regulators AMPK&#x3b1;1 and FOXO1 <italic>via</italic> negative feedback loops (<xref ref-type="bibr" rid="B10">10</xref>). Our recent data showed that mTORC1<sup>Strong</sup> signaling inhibits Yin AMPK&#x3b1;1 and FOXO1 expression in IL-2/T<sub>E</sub> cells, while mTORC1<sup>Weak</sup>-induced expression of AMPK&#x3b1;1 and FOXO1 promotes T cell memory in IL-15/T<sub>M</sub> cells (<xref ref-type="bibr" rid="B13">13</xref>). mTORC1-induced phosphorylation of AMPK&#x3b1;1 at S<sub>485</sub> blocks its phosphorylation at T<sub>172</sub> in IL-2/T<sub>E</sub> cells, whereas AMPK&#x3b1;1-mediated phosphorylation of its downstream target TSC2 at S<sub>1387</sub> weakens mTORC1 signaling in IL-15/T<sub>M</sub> cells (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B23">23</xref>). In addition, mTORC2-dependent phosphorylation of AKT at S<sub>473</sub> phosphorylates FOXO1 at T<sub>24</sub>, which inhibits FOXO1 by reducing its nuclear localization (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) (<xref ref-type="bibr" rid="B24">24</xref>). FOXO1 in turn is able to down-regulate mTORC1 signaling <italic>via</italic> its activation of sestrin, a suppressor of mTORC1 (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) (<xref ref-type="bibr" rid="B25">25</xref>). Collectively, these reports confirm the negative interplay between the master regulators Yin FOXO1 or AMPK&#x3b1;1 and Yang AKT/mTORC1 (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1A, E</bold>
</xref>d). In support of this principle, the AMPK activator metformin inhibits mTORC1 (<xref ref-type="bibr" rid="B26">26</xref>), while the mTORC1 inhibitor Rapa promotes AMPK&#x3b1;1 and FOXO1 activity (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1A, E</bold>
</xref>e) (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B14">14</xref>).</p>
<p>The theory also advances that the Yin response contains some Yang elements and <italic>vice versa</italic>, which facilitates their interconversion under certain conditions (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>f). For example, a basic feature of T<sub>M</sub> cells is their ability to rapidly proliferate and switch to functional T<sub>E</sub> cells in a recall response (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>). This interconversion is facilitated by the maintenance of an AKT-dependent, &#x201c;imprinted&#x201d; glycolytic potential (<xref ref-type="bibr" rid="B27">27</xref>) or a demethylated, epigenetic mark at the IFN-&#x3b3; promotor (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B28">28</xref>) inherited from the Yang CD8<sup>+</sup> T<sub>E</sub> precursor, either of which leads to an efficient immediate-early recall response of Yin CD8<sup>+</sup> T<sub>M</sub> cells upon cognate antigen re-encounter.</p>
<p>Differentiation of distinct immune cell subsets is accompanied by complementary changes in fuel preference. To date, the Yin and Yang metabolic pathways in all immune cell subsets are regulated by the Yin AMPK&#x3b1;1 for FAO and the Yang HIF-1&#x3b1; for glycolytic metabolism. In contrast, the Yin and Yang transcriptional factors controlling differentiation into a defined form and function may differ across immune cell subsets. For example, Yin GATA3 is stimulated in CD4<sup>+</sup> Th2 which use FAO while Yang T-bet is triggered in CD4<sup>+</sup> Th1 cells which rely on glycolysis (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B29">29</xref>). Similarly, Yin Foxp3, Smad3 and FOXO1 are activated in FAO reliant CD4<sup>+</sup> Treg cells while Yang ROR-&#x3b3;t is stimulated in glycolytic CD4<sup>+</sup> Th17 cells (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B30">30</xref>). Finally, Yin STAT6 and PPAR-&#x3b3; are up-regulated in FAO utilizing tolerant M2 cells while Yang STAT1 and NF-&#x3ba;B are stimulated in immunogenic M1 cells relying on glycolysis (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) (<xref ref-type="bibr" rid="B18">18</xref>). These data illustrate that the above principle can be used to interpret various cell subsets of the immune system and may perhaps be extended to cell subsets in various tissues and organs of the body (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>g).</p>
<p>The dynamic balance of Yin and Yang keeps the body healthy, and illness may result when there is an upset within or between these two systems (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>). A deficiency in CD4<sup>+</sup> Treg cells or inhibitory co-stimulation and a more active Yang T<sub>E</sub> cell response derived from some strong vaccinations can induce detrimental autoimmune and lymphoproliferative diseases, respectively (<xref ref-type="bibr" rid="B33">33</xref>&#x2013;<xref ref-type="bibr" rid="B35">35</xref>), while deficiencies in T-cell immunity may underlie infectious and cancerous diseases (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>h) (<xref ref-type="bibr" rid="B36">36</xref>).</p>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusion</title>
<p>Our current knowledge of various immune elements and genes (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) emphasizes the importance of the interplay between Yin and Yang molecular pathways that control immune responses or underlie various immune disorders (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Yet additional, integrative studies of large datasets using artificial intelligence or other technological approaches to analyze and interpret various genes and cell subsets are required to further improve our understanding of the molecular bases and pathways of the Yin-Yang theory in T-cell immunity in the context of human health and disease (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>). Nevertheless, this nascent model provides a new and simple guide with which to categorize genes into Yin and Yang groups, to facilitate the analysis of complex genetic networks and interactions between genetic elements and molecular pathways. Therefore, this model may act as a novel platform for drug innovation to combat various diseases (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>). Future studies in this direction should further strengthen the conceptional connection between TCM and WM, that will be greatly beneficial to human health.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>JX: Writing &#x2013; original draft. SL: Writing &#x2013; review &amp; editing. ZW: Writing &#x2013; review &amp; editing. MY: Writing &#x2013; review &amp; editing.</p>
</sec>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The work was financially supported by a research grant (#PJT153314) from the Canadian Institutes of Health Research (CIHR) to JX.</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Lowrie</surname> <given-names>DB</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>XY</given-names>
</name>
</person-group>. <article-title>Trained immunity: A Yin-Yang balance</article-title>. <source>MedComm (2020)</source>. (<year>2022</year>) <volume>3</volume>:<elocation-id>e121</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mco2.121</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allison</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Krummel</surname> <given-names>MF</given-names>
</name>
</person-group>. <article-title>The Yin and Yang of T cell costimulation</article-title>. <source>Science</source>. (<year>1995</year>) <volume>270</volume>:<page-range>932&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.270.5238.932</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Immunology in China: the past, present and future</article-title>. <source>Nat Immunol</source>. (<year>2008</year>) <volume>9</volume>:<page-range>339&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni0408-339</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hall</surname> <given-names>MN</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Hardie</surname> <given-names>DG</given-names>
</name>
</person-group>. <article-title>AMPK and TOR: the yin and yang of cellular nutrient sensing and growth control</article-title>. <source>Cell Metab</source>. (<year>2020</year>) <volume>31</volume>:<page-range>472&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmet.2020.01.015</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blondi</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Cheung</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Casayor</surname> <given-names>A</given-names>
</name>
<name>
<surname>Deak</surname> <given-names>M</given-names>
</name>
<name>
<surname>Currie RA and Alessi</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA</article-title>. <source>EMBO J</source>. (<year>2000</year>) <volume>19</volume>:<elocation-id>979</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/emboj/19.5.979</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Gan</surname> <given-names>W</given-names>
</name>
<name>
<surname>Chin</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ogura</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ogura</surname> <given-names>K</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Ptdlns(3,4,5)P3-dependent activation of the mTORC2 kinase complex</article-title>. <source>Cancer Disc</source>. (<year>2015</year>) <volume>5</volume>:<page-range>1194&#x2013;209</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0460</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Araki</surname> <given-names>K</given-names>
</name>
<name>
<surname>Turner</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Shaffer</surname> <given-names>VO</given-names>
</name>
<name>
<surname>Gangappa</surname> <given-names>S</given-names>
</name>
<name>
<surname>Keller</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Bachmann</surname> <given-names>MF</given-names>
</name>
<etal/>
</person-group>. <article-title>mTOR regulates memory CD8 T-cell differentiation</article-title>. <source>Nature</source>. (<year>2009</year>) <volume>460</volume>:<page-range>108&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature08155</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tschumi</surname> <given-names>BO</given-names>
</name>
<name>
<surname>Lopez-Mefia</surname> <given-names>IC</given-names>
</name>
<name>
<surname>Oberie</surname> <given-names>SG</given-names>
</name>
<name>
<surname>Meyer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Samson</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Mammalian target of rapamycin complex 2 controls CD8 T cell memory differentiation in a foxo1-dependent mannaer</article-title>. <source>Cell Rep</source>. (<year>2016</year>) <volume>14</volume>:<page-range>1206&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2015.12.095</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinberg</surname> <given-names>GR</given-names>
</name>
<name>
<surname>Hardie</surname> <given-names>DG</given-names>
</name>
</person-group>. <article-title>New insights into activation and function of the AMPK</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2023</year>) <volume>24</volume>:<page-range>255&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41580-022-00547-x</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>F</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Lazarovici</surname> <given-names>P</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Signaling network of forkhead family of transcription factors (FOXO) in dietary restriction</article-title>. <source>Cells</source>. (<year>2019</year>) <volume>9</volume>:<elocation-id>100</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells9010100</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonard</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>JX</given-names>
</name>
<name>
<surname>O&#x2019;Shea</surname> <given-names>JJ</given-names>
</name>
</person-group>. <article-title>The gamma(c) family of cytokines: basic biology to therapeutic ramifications</article-title>. <source>Immunity</source>. (<year>2019</year>) <volume>50</volume>:<page-range>832&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.028</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Leary</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Islam</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Bhanumathy</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Ara</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Prosurvival IL-7-Stimulated Weak Strength of mTORC1-S6K Controls T Cell Memory via Transcriptional FOXO1-TCF1-Id3 and Metabolic AMPKalpha1-ULK1-ATG7 Pathways</article-title>. <source>J Immunol</source>. (<year>2022</year>) <volume>208</volume>:<page-range>155&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.2100452</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ara</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ahmed</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Leary</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Islam</surname> <given-names>MF</given-names>
</name>
<etal/>
</person-group>. <article-title>The critical role of AMPKalpha1 in regulating autophagy and mitochondrial respiration in IL-15-stimulated mTORC1(Weak) signal-induced T cell memory: an interplay between yin (AMPKalpha1) and yang (mTORC1) energy sensors in T cell differentiation</article-title>. <source>Int J Mol Sci</source>. (<year>2022</year>) <volume>23</volume>:<elocation-id>9534</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms23179534</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ara</surname> <given-names>A</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ahmed</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Leary</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Islam</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>The energy sensor AMPKalpha1 is critical in rapamycin-inhibition of mTORC1-S6K-induced T-cell memory</article-title>. <source>Int J Mol Sci</source>. (<year>2021</year>) <volume>23</volume>:<elocation-id>37</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms23010037</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Leary</surname> <given-names>S</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Distinct strengths of mTORC1 control T-cell memory via transcriptional FOXO1 and metabolic AMPKalpha1 pathways in linear cell differentiation and asymmetric cell division models</article-title>. <source>Cell Mol Immunol</source>. (<year>2022</year>) <volume>19</volume>:<page-range>1073&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41423-022-00879-w</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hess Michelini</surname> <given-names>R</given-names>
</name>
<name>
<surname>Doedens</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Goldrath</surname> <given-names>AW</given-names>
</name>
<name>
<surname>Hedrick</surname> <given-names>SM</given-names>
</name>
</person-group>. <article-title>Differentiation of CD8 memory T cells depends on Foxo1</article-title>. <source>J Exp Med</source>. (<year>2013</year>) <volume>210</volume>:<page-range>1189&#x2013;200</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20130392</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saravia</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chapman</surname> <given-names>NM</given-names>
</name>
<name>
<surname>Chi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Helper T cell differentiation</article-title>. <source>Cell Mol Immunol</source>. (<year>2019</year>) <volume>16</volume>:<page-range>634&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41423-019-0220-6</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Saeed</surname> <given-names>A</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>GG</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophages in immunoregulation and therapeutics</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2023</year>) <volume>8</volume>:<fpage>207</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41392-023-01452-1</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dahmani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Janelle</surname> <given-names>V</given-names>
</name>
<name>
<surname>Carli</surname> <given-names>C</given-names>
</name>
<name>
<surname>Richaud</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lamarche</surname> <given-names>C</given-names>
</name>
<name>
<surname>Khalili</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>TGFbeta programs central memory differentiation in ex vivo-stimulated human T cells</article-title>. <source>Cancer Immunol Res</source>. (<year>2019</year>) <volume>7</volume>:<page-range>1426&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-18-0691</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Cytokine regulation and function in T cells</article-title>. <source>Annu Rev Immunol</source>. (<year>2021</year>) <volume>39</volume>:<fpage>51</fpage>&#x2013;<lpage>76</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-061020-053702</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schnell</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bod</surname> <given-names>L</given-names>
</name>
<name>
<surname>Madi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kuchroo</surname> <given-names>VK</given-names>
</name>
</person-group>. <article-title>The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity</article-title>. <source>Cell Res</source>. (<year>2020</year>) <volume>30</volume>:<page-range>285&#x2013;99</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41422-020-0277-x</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fitzgerald</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Kagan</surname> <given-names>JC</given-names>
</name>
</person-group>. <article-title>Toll-like receptors and the control of immunity</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>180</volume>:<page-range>1044&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.041</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Nostrand</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Hellberg</surname> <given-names>K</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>EC</given-names>
</name>
<name>
<surname>Van Nostrand</surname> <given-names>EL</given-names>
</name>
<name>
<surname>Dayn</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>AMPK regulation of Raptor and TSC2 mediate metformin effects on transcriptional control of anabolism and inflammation</article-title>. <source>Genes Dev</source>. (<year>2020</year>) <volume>34</volume>:<page-range>1330&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/gad.339895.120</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tschumi</surname> <given-names>BO</given-names>
</name>
<name>
<surname>Lopez-Mejia</surname> <given-names>IC</given-names>
</name>
<name>
<surname>Oberle</surname> <given-names>SG</given-names>
</name>
<name>
<surname>Meyer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Samson</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Mammalian target of rapamycin complex 2 controls CD8 T cell memory differentiation in a foxo1-dependent manner</article-title>. <source>Cell Rep</source>. (<year>2016</year>) <volume>14</volume>:<page-range>1206&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2015.12.095</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Jeon</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Bhaskar</surname> <given-names>PT</given-names>
</name>
<name>
<surname>Nogueira</surname> <given-names>V</given-names>
</name>
<name>
<surname>Sundararajan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Tonic</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor</article-title>. <source>Dev Cell</source>. (<year>2010</year>) <volume>18</volume>:<fpage>592</fpage>&#x2013;<lpage>604</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.devcel.2010.03.008</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howell</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Hellberg</surname> <given-names>K</given-names>
</name>
<name>
<surname>Turner</surname> <given-names>M</given-names>
</name>
<name>
<surname>Talbott</surname> <given-names>G</given-names>
</name>
<name>
<surname>Kolar</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Ross</surname> <given-names>DS</given-names>
</name>
<etal/>
</person-group>. <article-title>Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex</article-title>. <source>Cell Metab</source>. (<year>2017</year>) <volume>25</volume>:<page-range>463&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmet.2016.12.009</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gubser</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Bantug</surname> <given-names>GR</given-names>
</name>
<name>
<surname>Razik</surname> <given-names>L</given-names>
</name>
<name>
<surname>Fischer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Dimeloe</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hoenger</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch</article-title>. <source>Nat Immunol</source>. (<year>2013</year>) <volume>14</volume>:<page-range>1064&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.2687</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Windt</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>O&#x2019;Sullivan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Everts</surname> <given-names>B</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Buck</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Curtis</surname> <given-names>JD</given-names>
</name>
<etal/>
</person-group>. <article-title>CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2013</year>) <volume>110</volume>:<page-range>14336&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1221740110</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stark</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Tibbitt</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Coquet</surname> <given-names>JM</given-names>
</name>
</person-group>. <article-title>The metabolic requirements of th2 cell differentiation</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>2318</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.02318</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>T cell metabolism: A new perspective on th17/treg cell imbalance in systemic lupus erythematosus</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>1027</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.01027</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boutouja</surname> <given-names>F</given-names>
</name>
<name>
<surname>Stiehm</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Platta</surname> <given-names>HW</given-names>
</name>
</person-group>. <article-title>mTOR: A cellular regulator interface in health and disease</article-title>. <source>Cells</source>. (<year>2019</year>) <volume>8</volume>:<elocation-id>18</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells8010018</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeon</surname> <given-names>SM</given-names>
</name>
</person-group>. <article-title>Regulation and function of AMPK in physiology and diseases</article-title>. <source>Exp Mol Med</source>. (<year>2016</year>) <volume>48</volume>:<fpage>e245</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/emm.2016.81</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toussirot</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bereau</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Vaccination and induction of autoimmune diseases</article-title>. <source>Inflammation Allergy Drug Targets</source>. (<year>2015</year>) <volume>14</volume>:<page-range>94&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/1871528114666160105113046</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klocke</surname> <given-names>K</given-names>
</name>
<name>
<surname>Sakaguchi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Holmdahl</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wing</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2016</year>) <volume>113</volume>:<page-range>E2383&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1603892113</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dejaco</surname> <given-names>C</given-names>
</name>
<name>
<surname>Duftner</surname> <given-names>C</given-names>
</name>
<name>
<surname>Grubeck-Loebenstein</surname> <given-names>B</given-names>
</name>
<name>
<surname>Schirmer</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Imbalance of regulatory T cells in human autoimmune diseases</article-title>. <source>Immunology</source>. (<year>2006</year>) <volume>117</volume>:<fpage>289</fpage>&#x2013;<lpage>300</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1365-2567.2005.02317.x</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mortaz</surname> <given-names>E</given-names>
</name>
<name>
<surname>Tabarsi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Mansouri</surname> <given-names>D</given-names>
</name>
<name>
<surname>Khosravi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Garssen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Velayati</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancers related to immunodeficiencies: update and perspectives</article-title>. <source>Front Immunol</source>. (<year>2016</year>) <volume>7</volume>:<elocation-id>365</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2016.00365</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Modern bioinformatics meets traditional Chinese medicine</article-title>. <source>Brief Bioinform</source>. (<year>2014</year>) <volume>15</volume>:<fpage>984</fpage>&#x2013;<lpage>1003</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/bib/bbt063</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>B</given-names>
</name>
<name>
<surname>He</surname> <given-names>H</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Artificial intelligence and big data facilitated targeted drug discovery</article-title>. <source>Stroke Vasc Neurol</source>. (<year>2019</year>) <volume>4</volume>:<page-range>206&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/svn-2019-000290</pub-id>
</citation>
</ref>
</ref-list>
<glossary>
<title>Glossary</title>
<def-list>
<def-item>
<term>AMPK&#x3b1;1</term>
<def>
<p>adenosine monophosphate-activated protein kinase-&#x3b1;1</p>
</def>
</def-item>
<def-item>
<term>AQP9</term>
<def>
<p>aquaporin-9</p>
</def>
</def-item>
<def-item>
<term>ATG7</term>
<def>
<p>autophagy-related gene-7</p>
</def>
</def-item>
<def-item>
<term>BTLA</term>
<def>
<p>B and T lymphocyte attenuator</p>
</def>
</def-item>
<def-item>
<term>CaMKK2</term>
<def>
<p>Ca<sup>++</sup>/calmodulin-activated protein kinase kinase-2</p>
</def>
</def-item>
<def-item>
<term>cDC1</term>
<def>
<p>conventional type-1 dendritic cell</p>
</def>
</def-item>
<def-item>
<term>CPT1&#x3b1;</term>
<def>
<p>carnitine palmitoyl transferase-1&#x3b1;</p>
</def>
</def-item>
<def-item>
<term>CTLA-4</term>
<def>
<p>cytotoxic T lymphocyte-associated protein-4</p>
</def>
</def-item>
<def-item>
<term>DC</term>
<def>
<p>dendritic cell</p>
</def>
</def-item>
<def-item>
<term>eIF4E</term>
<def>
<p>eukaryotic translation initiation factor-4E</p>
</def>
</def-item>
<def-item>
<term>FAO</term>
<def>
<p>fatty acid oxidation</p>
</def>
</def-item>
<def-item>
<term>FOXO1</term>
<def>
<p>forkhead box-O1</p>
</def>
</def-item>
<def-item>
<term>Foxp3</term>
<def>
<p>forkhead box-P3</p>
</def>
</def-item>
<def-item>
<term>iDC</term>
<def>
<p>immature dendritic cell</p>
</def>
</def-item>
<def-item>
<term>GATA3</term>
<def>
<p>GATA-binding protein-3</p>
</def>
</def-item>
<def-item>
<term>GSK3&#x3b2;</term>
<def>
<p>glycogen synthase kinase-3 beta</p>
</def>
</def-item>
<def-item>
<term>ID3</term>
<def>
<p>DNA binding-3</p>
</def>
</def-item>
<def-item>
<term>KLRG1</term>
<def>
<p>killer cell lectin-like receptor G1</p>
</def>
</def-item>
<def-item>
<term>LAG3</term>
<def>
<p>lymphocyte-activation gene-3</p>
</def>
</def-item>
<def-item>
<term>LAL</term>
<def>
<p>lysosomal acid lipase</p>
</def>
</def-item>
<def-item>
<term>LKB1</term>
<def>
<p>liver kinase-B1</p>
</def>
</def-item>
<def-item>
<term>M1</term>
<def>
<p>type-1 macrophage</p>
</def>
</def-item>
<def-item>
<term>M2</term>
<def>
<p>type-2 macrophage</p>
</def>
</def-item>
<def-item>
<term>mDC</term>
<def>
<p>mature dendritic cell</p>
</def>
</def-item>
<def-item>
<term>mTORC1</term>
<def>
<p>mammalian target of rapamycin complex-1</p>
</def>
</def-item>
<def-item>
<term>NF-&#x3ba;B1</term>
<def>
<p>nuclear-factor kappa-B subunit-1</p>
</def>
</def-item>
<def-item>
<term>OPA-1</term>
<def>
<p>optic atrophy-1</p>
</def>
</def-item>
<def-item>
<term>PCG1&#x3b1;</term>
<def>
<p>peroxisome proliferator-activated receptor-&#x3b3; coactivator-1&#x3b1;</p>
</def>
</def-item>
<def-item>
<term>PD-1</term>
<def>
<p>programmed cell death protein-1</p>
</def>
</def-item>
<def-item>
<term>PDK1</term>
<def>
<p>phosphoinositide-dependent kinase-1</p>
</def>
</def-item>
<def-item>
<term>PKA</term>
<def>
<p>cAMP-activated protein kinase A</p>
</def>
</def-item>
<def-item>
<term>PI3K</term>
<def>
<p>PI3 kinase</p>
</def>
</def-item>
<def-item>
<term>PIP2</term>
<def>
<p>phosphatidylinositol 4,5-bisphosphate</p>
</def>
</def-item>
<def-item>
<term>PIP3</term>
<def>
<p>phosphatidylinositol 3,4,5-trisphosphate</p>
</def>
</def-item>
<def-item>
<term>PPAR-&#x3b3;</term>
<def>
<p>peroxisome proliferator-activated receptor-&#x3b3;</p>
</def>
</def-item>
<def-item>
<term>PTEN</term>
<def>
<p>phosphatase and tension homolog</p>
</def>
</def-item>
<def-item>
<term>Rapa</term>
<def>
<p>rapamycin</p>
</def>
</def-item>
<def-item>
<term>S6K1</term>
<def>
<p>S6 kinase-1</p>
</def>
</def-item>
<def-item>
<term>S6K2</term>
<def>
<p>S6 kinase-2</p>
</def>
</def-item>
<def-item>
<term>SIRT1</term>
<def>
<p>silent information-regulator of transcription-1</p>
</def>
</def-item>
<def-item>
<term>STAT6</term>
<def>
<p>signal transducer/transcription activator-6</p>
</def>
</def-item>
<def-item>
<term>TAK-1</term>
<def>
<p>TGF-&#x3b2;-activated kinase-1</p>
</def>
</def-item>
<def-item>
<term>TCF1</term>
<def>
<p>T cell factor-1</p>
</def>
</def-item>
<def-item>
<term>T<sub>E</sub>
</term>
<def>
<p>effector T</p>
</def>
</def-item>
<def-item>
<term>TFAM</term>
<def>
<p>mitochondrial transcription factor-A</p>
</def>
</def-item>
<def-item>
<term>Th1</term>
<def>
<p>type-1 helper T</p>
</def>
</def-item>
<def-item>
<term>Th2</term>
<def>
<p>type-2 helper T</p>
</def>
</def-item>
<def-item>
<term>TIGIT</term>
<def>
<p>T cell immunoglobulin and ITIM domain</p>
</def>
</def-item>
<def-item>
<term>TIM3</term>
<def>
<p>timeless-3</p>
</def>
</def-item>
<def-item>
<term>TLR</term>
<def>
<p>Toll-like receptor</p>
</def>
</def-item>
<def-item>
<term>T<sub>M</sub>
</term>
<def>
<p>memory T</p>
</def>
</def-item>
<def-item>
<term>Tn</term>
<def>
<p>na&#xef;ve T</p>
</def>
</def-item>
<def-item>
<term>Treg</term>
<def>
<p>regulatory T</p>
</def>
</def-item>
<def-item>
<term>TSC2</term>
<def>
<p>TSC complex subunit 2</p>
</def>
</def-item>
<def-item>
<term>ROR-&#x3b3;t</term>
<def>
<p>retinoid-related orphan receptor-&#x3b3;t</p>
</def>
</def-item>
<def-item>
<term>ULK1</term>
<def>
<p>Unc-51-like autophagy-activating kinase-1.</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>